News | May 14, 2024
Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
EBITDA before special items falls 1.3 percent to € 4.41 billion
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Lupin updates on shipment of Mirabegron ER Tablets
Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
The company has posted net profit of Rs. 1,201.22 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
